Navigation Links
Nutraceutical Reports 2008 Fiscal Year End Results
Date:11/20/2008

ent assets, net $55,577 $51,534 Property, plant and equipment, net 52,356 39,506 Goodwill 37,632 38,978 Other non-current assets, net 16,099 16,384 $161,664 $146,402 Liabilities and Stockholders' Equity Current liabilities $19,239 $20,275 Long-term liabilities 28,965 20,208 Stockholders' equity 113,460 105,919 $161,664 $146,402 NUTRACEUTICAL INTERNATIONAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited; dollars in thousands, except per share data) Three months ended Twelve months ended September 30, September 30, 2008 2007 2008 2007 Net sales $40,899 $39,902 $166,885 $156,548 Cost of sales 18,914 18,429 76,106 71,622 Gross profit 21,985 21,473 90,779 84,926 Operating expenses Selling, general and administrative 16,434 16,217 66,973 61,905 Amortization of intangible assets 179 161 701 391 Impairment of goodwill and intangible asset 2,875 450 2,875 450 Income from operations 2,497 4,645 20,230 22,180 Interest and other (income)/expense, net 262 443 1,270 1,257 Income before provision for income taxes
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
3. Nutraceuticals could prevent diabetes
4. Nutraceutical Reports Q3 Results
5. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
6. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
7. Berkeley Premium Nutraceuticals Pushes Forward
8. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
9. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
10. Nutraceutical Reports Fiscal 2008 Q1 Results
11. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4Colorectal cancer 9090 1Genetically engineered mice yield clues to knocking out cancer 9086 1Genetically engineered mice yield clues to knocking out cancer 9086 2